- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03819491
Bioavailability Study of COQUN ORAL FORMULATION
Bioavailability Study of COQUN ORAL FORMULATION (CoQ10) Administered in Healthy Adults (CoQ10-01)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will include 24 healthy subjects who will test the CoQ10 formulation. All 24 subjects will test a single dose of 100mg CoQ10 in 1 day to assess bioavailability, which will be followed by a one week wash-out period and then by a 4 week period of continuous administration of COQUN ORAL FORMULATION in parallel groups (1:1): patients will be divided in the continuous treatment period into two groups, one group of 12 patients with intake of 100mg OD, the other one group of 12 patients with intake of 100mg BID, in order to assess multiple-dose profile of COQUN ORAL FORMULATION.
Patients will have to fast the night before enrolment, for at least 10 hours. Patients will be requested to fill in a short diary in the multidose phase, on a daily basis, for confirming the product correct intake, and informing on any experienced adverse event and eventual medication taken for its solving.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Iasi County, Romania
-
Iasi, Iasi County, Romania, Romania, 550
- Consult Med Iasi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject Informed consent form (ICF) is signed
- M & F Aged between 35-75 years at the time of the signature of ICF
- A body mass index between 20 and 29 kg/m2
- Fasting the night before enrolment, for at least 10 hours
- Healthy, meaning absence of any prescribed medication for a month prior to the inclusion to the study and during the study
- Willing to avoid a consumption of any food supplements except vitamin D and calcium at least 2 weeks before and during the study
- Consumption of dairy and cereal products (standardized breakfast will include low lactose dairy and bread)
- Willing to follow all study procedures, including attending all site visits (including sessions during which a venous line will be inserted for blood sampling), and keeping a diary for the time of multiple-dose study (to follow their compliance and palatability)
Exclusion Criteria:
- Intake of any prescribed medication within 2 weeks of the beginning of the study
- Intake of any food supplements within 2 weeks of the beginning of the study, except vitamin D and calcium
- Hypotension
- Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease, diabetes
- Gastrointestinal disorders or other serious acute or chronic diseases
- Known lactose/gluten intolerances/ food allergies (limitation for standardization of meals)
- Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
- Known drug and/or alcohol abuse
- Using any form of nicotine or tobacco
- Mental incapacity that precludes adequate understanding or cooperation
- Participation in another investigational study or blood donation within 3 months prior to or during this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
100 mg OD
|
COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
|
Experimental: Group B
100 mg BID
|
COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of Pharmacokinetic Property "Area Under the Curve"
Time Frame: from day-7 to day 28
|
- Area under the curve (microg/ml x h): ≥5 Due to the explorative aim of the study, descriptive statistics and confidence intervals at 95% level will be provided. Data were collected at 1, 2, 4, 8 and 12 hours after intake on the single dose period (day -7) and at each following ambulatory visit. |
from day-7 to day 28
|
Analysis of Pharmacokinetic Property "Cmax"
Time Frame: from day-7 to day 28
|
- Cmax: ≥0,8 Due to the explorative aim of the study, descriptive statistics and confidence intervals at 95% level will be provided. Data were collected at 1, 2, 4, 8 and 12 hours after intake on the single dose period (day -7) and at each following ambulatory visit. |
from day-7 to day 28
|
Analysis of Pharmacokinetic Property "Tmax"
Time Frame: from day-7 to day 28
|
- Tmax: ≥3 Due to the explorative aim of the study, descriptive statistics and confidence intervals at 95% level will be provided. Data were collected at 1, 2, 4, 8 and 12 hours after intake on the single dose period (day -7) and at each following ambulatory visit. |
from day-7 to day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- VF-BAQ10/2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male & Female Healthy Volunteers
-
Clene NanomedicineCompletedHealthy Volunteers - Male and FemaleNetherlands
-
Universitätsklinikum Hamburg-EppendorfWithdrawnHealthy Male and Female VolunteersGermany
-
PfizerCompletedHealthy Male and Female Japanese VolunteersUnited States
-
Intarcia TherapeuticsCompletedHealthy Adult Male and Female VolunteersNetherlands
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHealthy Adult Male and Female Volunteers
-
Avanir PharmaceuticalsCompletedHealthy Adult Male and Female VolunteersUnited States
-
AstraZenecaCompletedHealthy Japanese Young and Elderly Male and Non-fertile Female VolunteersJapan
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on COQUN ORAL FORMULATION
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Cylene PharmaceuticalsUnknownBreast Cancer | Multiple Myeloma | Advanced Solid Tumors | Inflammatory Breast Cancer | Castleman's DiseaseUnited States
-
Glo Science, Inc.EEC Institute, Inc.CompletedPeriodontal Diseases | Tooth DiscolorationUnited States
-
AstraZenecaQuotient SciencesCompleted
-
ViiV HealthcareGlaxoSmithKlineNot yet recruiting
-
You First ServicesCompletedXerostomia | Dry Mouth | Type 2 DiabeticsUnited States
-
Janssen Research & Development, LLCWithdrawn
-
Johnson & Johnson Pharmaceutical Research & Development...Completed